Secarna Pharmaceuticals Announces Publication of New Preclinical Data Showing Durable Antitumor Activity of LNAplus(TM)-Based ASOs that Both Stimulate the Innate Immune System and Suppress PD-L1 Expression newjerseytelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newjerseytelegraph.com Daily Mail and Mail on Sunday newspapers.
Compelling in vivo and in vitro data published in peer-reviewed Journal for ImmunoTherapy of Cancer (JITC)Secarna's LNAplus-based ASOs effectively stimulate TLR9 signaling, an important innate immune pathway